دورية أكاديمية
أعرض في EDS

Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex .

التفاصيل البيبلوغرافية
العنوان: Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex .
المؤلفون: Garcia RCL; Medical Sciences Post-Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil., Rodrigues RD; Healthcare-Associated Infection Control Service, Hospital Universitário Professor Polydoro Ernani de São Thiago, Universidade Federal de Santa Catarina, Florianópolis 88036-800, Brazil., Garcia ECL; Medical School, Pontifícia Universidade Católica do Paraná, Curitiba 80215-901, Brazil., Rigatto MH; Medical Sciences Post-Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil.; Internal Medicine Department, School of Medicine of the Federal University of Rio Grande do Sul, Porto Alegre 90035-903, Brazil.; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, 2350 Ramiro Barcelos St, Porto Alegre 90035-903, Brazil.
المصدر: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2023 Aug 15; Vol. 12 (8). Date of Electronic Publication: 2023 Aug 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382 (Print) Linking ISSN: 20796382 NLM ISO Abbreviation: Antibiotics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2012-
مستخلص: Polymyxins are still widely used for the treatment of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bloodstream infections (BSIs). This study seeks to evaluate the impact of polymyxin B versus colistin on mortality and nephrotoxicity in BSI caused by these bacteria. We conducted a retrospective cohort study from 2014 to 2021 in Porto Alegre, Brazil. We included patients aged ≥18 years and excluded patients with polymicrobial infection or treatment for ≤48 h. The 30-day mortality was the primary outcome evaluated through Cox regression. We included 259 patients with BSI episodes: 78.8% caused by A. baumannii and 21.2% caused by P. aeruginosa . Polymyxin B did not impact mortality compared to colistin (adjusted hazard ratio (aHR), 0.82; 95% confidence interval (CI), 0.52-1.30; p = 0.40 (when adjusted for COVID-19 comorbidity, p = 0.05), Pitt bacteremia score, p < 0.01; Charlson comorbidity index, p < 0.001; time to start active antimicrobial therapy, p = 0.02). Results were maintained in the subgroups of BSI caused by A. baumannii (aHR, 0.92; 95% CI, 0.55-1.54; p = 0.74), P. aeruginosa (aHR, 0.47; 95% CI, 0.17-1.32; p = 0.15) and critical care patients (aHR, 0.77; 95% CI, 0.47-1.26; p = 0.30). Treatment with polymyxin B or colistin did not impact 30-day mortality in patients with carbapenem-resistant A. baumannii or P. aeruginosa BSI.
References: Clin Microbiol Infect. 2021 Jan 6;:. (PMID: 33359542)
Pharmacol Res. 2021 Jan;163:105328. (PMID: 33276108)
Expert Rev Anti Infect Ther. 2015;13(12):1481-97. (PMID: 26488563)
Shock. 2009 Feb;31(2):146-50. (PMID: 18636041)
Lancet Infect Dis. 2015 Feb;15(2):225-34. (PMID: 25459221)
Crit Care. 2004 Aug;8(4):R204-12. (PMID: 15312219)
Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93. (PMID: 20014903)
Clin Microbiol Rev. 2021 Mar 10;34(2):. (PMID: 33692149)
Diagn Microbiol Infect Dis. 2009 Dec;65(4):431-4. (PMID: 19733029)
Int J Antimicrob Agents. 2016 Dec;48(6):592-597. (PMID: 27793510)
BMC Infect Dis. 2023 May 25;23(1):351. (PMID: 37231342)
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528. (PMID: 31724045)
Antimicrob Agents Chemother. 2014 May;58(5):2740-6. (PMID: 24566187)
Int J Antimicrob Agents. 2017 Feb;49(2):233-238. (PMID: 27686609)
Int J Antimicrob Agents. 2014 Apr;43(4):349-52. (PMID: 24439066)
Expert Rev Anti Infect Ther. 2007 Oct;5(5):811-21. (PMID: 17914915)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Pharmacotherapy. 2019 Jan;39(1):10-39. (PMID: 30710469)
Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 31010862)
Clin Microbiol Infect. 2020 Feb;26(2):158-167. (PMID: 31733377)
Clin Infect Dis. 2014 Jul 1;59(1):88-94. (PMID: 24700659)
Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051)
Clin Infect Dis. 2013 Aug;57(4):524-31. (PMID: 23697744)
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2443-9. (PMID: 26856846)
فهرسة مساهمة: Keywords: Acinetobacter baumannii; Pseudomonas aeruginosa; bloodstream infection; colistin; polymyxin B
تواريخ الأحداث: Date Created: 20230826 Latest Revision: 20230828
رمز التحديث: 20230828
مُعرف محوري في PubMed: PMC10451820
DOI: 10.3390/antibiotics12081317
PMID: 37627737
قاعدة البيانات: MEDLINE
الوصف
تدمد:2079-6382
DOI:10.3390/antibiotics12081317